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ABSTRACT 
OBJECTIVE: 
The objective of this selective EBM review is to determine whether or not allogeneic SCT of HR 
pediatric ALL patients is more effective in preventing future relapses of disease and/or mortality 
in comparison with chemotherapeutic regimens alone.   
 
STUDY DESIGN: 
Review of three English language primary randomized controlled trial studies published between 
1996 and the present.   
 
DATA SOURCES: 
Randomized controlled trial studies were found using PubMed. 
 
OUTCOMES MEASURED:   
Each of the three studies evaluated the incidence of recurrent disease and/or mortality in high-
risk pediatric ALL patients.  These outcomes were analyzed according to the following 
categories: duration of event-free survival (EFS); duration of disease-free survival (DFS); 
incidence of relapses; complete remission (CR); death; partial response (PR); resistant disease 
(RD); and overall survival (OS).   
 
RESULTS:  
Three randomized controlled trials were included in this review.  The study by Schrauder et. al., 
which analyzed the role of SCT in first complete remission for children with very high-risk ALL, 
showed that the OS for patients who received SCT was higher than that of the patients who 
received chemotherapy alone (67% vs. 47%).  In the study by Ribera et. al. comparing the 
options of chemotherapy alone versus allogeneic SCT as post-remission therapy, the DFS and 
OS were both used as indicators of success and showed higher percentages of both in the 
subgroup that received chemotherapy alone.  The final study by Tallen et. al. analyzed a 
multicenter trial (ALL-REZ BFM 90), which was created with the purpose of improving the 
prognosis for children with relapsed ALL.  The results of this study demonstrated significant 
differences in the probabilities of EFS and OS amongst the different subgroups analyzed 
indicating that remission induction regimens must be improved and that allogeneic SCT should 
be recommended in patients achieving a second complete remission. 
 
CONCLUSIONS: 
Two out of three studies included in this review support the use of allogeneic SCT versus 
chemotherapeutic regimens alone when treating high-risk pediatric ALL patients.  Various 
factors, such as the achievement of first versus second remission, can also affect the results of 
studies involving this patient population. 
 
KEY WORDS:  
Allogeneic stem cell transplantation, acute lymphoblastic leukemia, pediatric 
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INTRODUCTION 
 
Pediatric acute lymphoblastic leukemia (ALL) is a malignant disease of the blood and 
bone marrow, that initiates with the lymphocytes (or lymphoblasts, an immature lymphocyte), a 
specific type of white blood cell (WBC) in the bone marrow, that are crucial in immune system 
functioning.  Once ALL develops, it then invades the bloodstream and can infest various organs, 
such as the liver, spleen, and lymph nodes.
1 
Pediatric ALL has a rapid onset of symptoms that 
can be fatal if not immediately treated. Symptoms of pediatric ALL are often vague and can 
mimic many other medical conditions making it difficult to diagnose at times; therefore, it is 
important for practicing physician assistants (PA) to be more aware of this deadly disease since it 
can cross over into many scopes of PA practice (i.e. family medicine, general pediatrics) and 
should be recognized so that prompt treatment can be initiated.  
Although it is recognized as one of the more “curable” types of childhood cancer, 
approximately 30% of patients relapse.
2
 Various prognostic factors of pediatric ALL patients 
include age and WBC count at the time of diagnosis, type of lymphocyte involved, specific 
chromosomal translocations, and patient’s response to induction chemotherapy.2 Patients with T-
cell ALL, infants and adolescents diagnosed with ALL, and those with Philadelphia-
chromosome positivity (Ph+) have historically had a poor prognosis and are considered high-risk 
(HR).
2
 These HR patients need more aggressive treatment regimens than the typical pediatric 
ALL patient who is usually between the ages of 1 and 9 years old. 
2
 
Pediatric ALL is the most common malignancy diagnosed in children with the peak 
incidence in children aged 2-5 years.
5
 It accounts for nearly 1/3 of all pediatric cancer leading to 
about 2500-3500 new pediatric ALL diagnoses annually in the United States.
 5
  The exact cost of 
treatment for ALL patients has not yet been identified; however, it has been determined that the 
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addition of stem cell transplantation (SCT) to traditional chemotherapeutic regimens results in 
longer hospital stays and increased health care costs.
4
 The precise number of health care visits 
each year for HR pediatric ALL patients is also not identified at this time, but is documented that 
more than 40,000 children undergo treatment for childhood cancer each year.
3 
The exact cause of 
pediatric ALL remains largely unknown; however, few cases have been linked to associated 
inherited genetic syndromes (i.e. Down’s Syndrome), various viruses (i.e. prenatal exposure to 
influenza or varicella), and certain environmental factors (i.e. exposure to ionizing radiation ).
 5
 It 
is known that with improvements in diagnosis and treatment, overall cure rates for children with 
ALL approach 80%. 
5
 
 The gold standard for pediatric ALL treatment involves various chemotherapeutic 
regimens alone using a risk-based approach taking into account the prognostic factors previously 
mentioned.  HR patients are often recommended to receive an allogeneic SCT, which is a 
controversial topic in this field of medicine since the SCT process can be extremely toxic for a 
child to endure involving very high doses of chemotherapy and sometimes radiation therapy 
prior to SCT.  The method of treatment involving chemotherapy plus allogeneic SCT is being 
proposed for HR pediatric ALL patients in an effort to find a therapeutic approach that can 
improve the overall cure rate for this vulnerable patient population without causing a significant 
increase in mortality and morbidity rates.   
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not allogeneic 
SCT of HR pediatric ALL patients is more effective in preventing future relapses of disease 
and/or mortality in comparison with chemotherapeutic regimens alone.  
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METHODS 
 All three studies in this review were randomized controlled trials (RCT) and required a 
population of pediatric ALL patients considered to be HR with each study using varying criteria 
to make this determination.  Two out of the three also involved HR pediatric ALL patients 
enrolled on specific clinical trials such as ALL-BFM 90 and 95 and ALL-REZ BFM 90 (please 
refer to Table 1 for more details regarding these studies). Each study in this review differed in 
terms of the exact treatment protocol they used and evaluated, but all of them involved a variety 
of chemotherapeutic regimens and allogeneic SCT.  The comparison group in all studies 
involved various subgroups of HR pediatric ALL patients receiving chemotherapeutic regimens 
alone. All outcomes analyzed qualified as patient oriented evidence that matters (POEM) and 
included looking at incidence of recurrent disease and/or mortality in HR pediatric ALL patients. 
A detailed search using PubMed was completed by the author using key words such as 
allogeneic stem cell transplantation; acute lymphoblastic leukemia; and pediatric. All articles 
were in English and published in a peer reviewed journal (Journal of Clinical Oncology) between 
2006 and 2010.  The author of this selective EBM review conducted the research of the articles 
used and articles were selected based on the importance of outcomes in patients (i.e. POEMS) 
and on their relevance to the topic question.  Inclusion and exclusion criteria varied amongst the 
three studies in this review and are outlined in Table 1. The summary of statistics reported 
and/or used include p-values, 95% confidence intervals (CI), various probabilities, and number 
needed to harm (NNH). 
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Table 1- Demographics & Characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion  
Criteria 
W/D Interventions 
Schrauder7, 
2006 
Randomized 
Controlled 
Trial 
 
 
179 0-18 Pediatric oncology pts up to 
18 yrs old enrolled onto the 
ALL-BFM 90 and 95 on 
treatment of childhood ALL 
in 96 participating centers 
in Germany, Austria, and 
Switzerland 
studies in Germany, 
Austria, and Switzerland 
 
N/A 0 Various 
chemotherapeutic 
regimens alone vs. 
Allogeneic stem cell 
transplantation 
 
Ribera 6, 
2007` 
Randomized 
Controlled 
Trial 
 
 
106 0-18 Pediatric high-risk ALL pts 
who are: 
-Age younger than 1 year 
-WBC count >  300 X 109/ 
L in B-lineage ALL 
-WBC count > 100 X 109/ L 
in T-lineage ALL 
-t(9;22), t(4;11), or other 
11q23 rearrangements; can 
also qualify if they have a  
slow or partial response to 
induction therapy protocols 
 
 
Patients who did 
not achieve 
complete 
remission after 
receiving the 
first cycle of 
early 
intensification 
chemotherapy 
 
11 Various 
chemotherapeutic 
regimens alone divided 
into various phases (i.e. 
induction; early 
intensification 1, 2, and 
3; delayed 
intensification 1,2, and 
3); Allogeneic and 
autologous stem cell 
transplantation 
 
Tallen 9, 
2010 
Randomized 
Controlled 
Trial 
 
525 0-18 Pediatric oncology patients 
with first  relapse of T- or 
B- cell precursor Acute 
Lymphoblastic Leukemia 
(ALL) younger than 19 
years of age; Patients 
enrolled on trial ALL-REZ 
BFM 90, which was 
conducted in 80 hospitals 
that recruited all children 
with relapsed ALL in 
Germany, Austria, and 
selected centers in 
Switzerland, the 
Netherlands, Denmark, and 
Russia after approval by 
each local ethics committee 
 
 
N/A 0 Alternating short-course 
intensive 
polychemotherapy and 
cranial/ craniospinal 
irradiation followed by 
maintenance therapy; 
Allogeneic Stem cell 
transplantation 
 
 
 
OUTCOMES MEASURED 
In the study by Schrauder et al., the HR group of patients were defined as the following: 
prednisone poor response (PPR; > 1,000 blasts/µL in peripheral blood after 1 week of prednisone 
and one intrathecal dose of methotrexate), nonresponse on day33 (NRd33; > 5% blasts in bone 
marrow on day 33), or positivity for translocations (i.e. t(9;22) or t(4;11) or MLL/AF4 or 
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BCR/ABL rearrangement).
7
 The outcomes measured in this study were overall survival (OS) rate 
and mortality rate for this subgroup of patients and were measured by comparing a group of HR 
patients who received chemotherapy alone (different regimens were used in ALL-BFM 90 
compared to ALL-BFM 95) to a group that received allogeneic SCT. The authors of this study 
monitored very specific outcomes including duration of event-free survival (EFS) and duration 
of disease-free survival (DFS).  EFS is defined as the times from diagnosis until the date of the 
first event (i.e. relapse, death from any reason, secondary malignancy), or if no such event 
occurred, until the date of the last contact.  DFS involved patients who achieved remission and 
was defined as the time from complete remission (CR) until the date of the first event (as stated 
above).
7
 
In the study by Ribera et al., improvement of prognosis for HR pediatric ALL patients 
and their mortality rates were the identified outcomes chosen to be analyzed (refer to Table 1 for 
HR criteria).
6
  This study particularly evaluated the outcomes of patients who achieved CR after 
receiving the first cycle of early intensification therapy. These patients were divided into two 
groups with one group receiving allogeneic SCT (if they had an HLA-identical sibling donor) 
and compared to a group of patients who received delayed intensification chemotherapy 
followed by maintenance treatment.  The authors of this study measured the outcomes by 
specifically monitoring the DFS (calculated from the date of CR until the date of first relapse, 
death by any cause, or the last follow-up for patients alive in first CR) and OS (measured from 
the time of entry in the protocol to the time of death or last follow-up).
6
   
Tallen et al., authors of the final study in this review, particularly looked at pediatric ALL 
patients with first relapse of T-or B- cell precursor ALL younger than 19 years of age who were 
enrolled on the ALL-REZ BFM 90 trial.
9  
The outcomes they chose to evaluate were 
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improvement of prognosis to ensure EFS and OS.  The patients were stratified into three 
subgroups based on the specific characteristics of their relapse along with a poor prognosis group 
(PPG) who had very early bone marrow relapse or any relapse of T-cell lineage.  The progress on 
treatment of each patient subgroup was closely monitored for incidences of relapse.
9 
RESULTS 
 In the study conducted by Ribera et al., patients deemed eligible (n=100) for the study 
were divided into various subgroups according to the HR category that they identified with (i.e. 
Infant ALL, ALL with specific cytogenetic translocations, B-lineage ALL without specific 
rearrangements, T-cell ALL, and slow/ partial responders to induction therapy) and were 
analyzed as such.
6
  Each subgroup of HR pediatric ALL patients had a set of patients that were 
randomized to receive an allogeneic SCT if they had an HLA-matched sibling donor (MSD) and 
a number of patients in that subgroup were randomly assigned to receive chemotherapy alone 
without SCT.  Of the 100 eligible patients, 24 were randomly assigned to receive allogeneic SCT 
and 38 were randomized to receive chemotherapy without SCT.  In the analysis of subgroups, 17 
patients actually received an allogeneic SCT (4 patients relapsed before transplant time and 3 
moved to the chemotherapy group) and 38 received chemotherapy alone.  Amongst the patient 
subgroup that received allogeneic SCT, 9 out of 17 remained in CR compared to 18 out of 38 in 
the group that received only chemotherapy.  Out of the slow/partial responders to induction 
therapy group, 7 out of 12 receiving SCT remained in CR compared to 10 out of 21 who 
received chemotherapy alone.  Overall, when the intervention group was compared to the control 
group, there were no significant differences in DFS for any subgroup (DFS probabilities=40% 
for SCT and 47% for chemotherapy).
6 
The intention-to-treat analysis in this study also showed 
no difference in the overall effects of each subgroup when comparing the groups that received an 
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allogeneic SCT versus those that only received chemotherapy (Table 2).
6
 It was concluded that 
their OS and DFS did not significantly differ from those of patients who received chemotherapy 
alone. In summary, at the end of the trial there were 10 patients alive in CR out of 24 that were 
assigned to receive an allogeneic SCT and 15 alive out of 38 who were assigned to receive 
chemotherapy alone.
6 
Table 2- Statistical Analysis of the Comparison of DFS, OS, and Relapse Probability for 
Patient Subgroups (i.e. donor vs. no donor/ patients who received chemotherapy alone) 
 Variable # of pts Median 
Yrs. F/U 
Median 
(Years) 
95% CI 5-Year 
Probability 
5-Year 
95% CI 
OS        
 Donor/ SCT 24 7.5 3.0 NC 48 30-67 
 Chemotherapy 38 5.9 NA NC 57 43-73 
DFS        
 Donor/ SCT 24 7.5 1.4 NC 45 27-65 
 Chemotherapy 38 5.8 2.9 NC 46 32-62 
        
Relapse 
probability  
       
 Donor/SCT 22 6.8 NA NC 33 12-56 
 Chemotherapy 36 5.4 NA NC 47 31-61 
**OS- Overall Survival; DFS- Disease-Free Survival; Relapse Probability- from beginning of late intensification 
therapy; NA- Not achieved; NC- Not Computable 
 
 The study by Schrauder et al., involving clinical trials ALL-BFM 90 and 95, deemed 191 
of 4,347 patients eligible to receive a MSD-SCT because of PPR and/or NRd33 (104 patients in 
ALL-BFM 90 and 87 patients in ALL-BFM 95).
7
  36 out of 76 patients who reached CR 
received an SCT.  In ALL-BFM 90, 10 patients received a MSD-SCT and 86 patients were 
treated with chemotherapy alone.  An adjustment was made for a minimum follow-up of 0.43 
years post diagnosis, which was the medium time to transplantation.  This adjustment resulted in 
a DFS rate at 5 years of 35% +/- 6% for the patients treatment with chemotherapy alone and 50% 
+/- 16% for the patients who received SCT (P=.27).
7
  57 out of 83 patients in the ALL-BFM 95 
trial were treated with chemotherapy alone and 26 patients received SCT.  In this trial, they also 
used matched unrelated donors (MUD) and mismatched family donors (MMFD) and the results 
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amongst these patient subgroups were further analyzed.  These groups were combined to 
enhance the overall effect of further analysis. There was no significant difference when 
comparing the DFS rate at 5 years of the SCT and chemotherapy groups in ALL- BFM 95 
(P=.09).  Overall, for both treatment regimens (SCT vs. chemotherapy alone) results were better 
in the ALL-BFM 95 trial; however, both trials were able to demonstrate a statistically significant 
difference in the DFS at 5 years between the control and intervention groups indicating that 
allogeneic SCT significantly improved the results achieved by chemotherapy alone (DFS at 5 
years, 67% +/- 8% v. 42% +/- 5%, respectively; P=.01).
7
  OS at 5 years also yielded similar 
results with the same statistics previously mentioned for DFS.
7 
There was a significant decrease 
in relapse incidence between the two trials in this study (69% +/- 5%, 59 of 86 patients; 46% +/- 
8%, 26 of 57 patients; P= .004) for the patients who received chemotherapy alone.
7
  On the other 
hand, there was an increase in the incidence of death for patients in CR within the same subgroup 
(Table 3).  For patients who received SCT, there was a difference in relapse incidence amongst 
the MSD-SCT and MUD/MMFD-SCT subgroups (MSD-SCT=8 of 23 patients; MUD/MMFD-
SCT=0 of 13 patients; P=.0001).
7
 Please refer to Table 3 for specific adverse effects in this 
patient group.
7
 The number needed to harm (NNH) in this study was calculated to be 17 patients.  
Table 3- Adverse Effects: HSCT vs. Chemotherapy Alone Subgroups 
 Variable # of Pts Deaths Other 
Adverse 
Events 
P-Values 
ALL-BFM 90      
 SCT 10 - -  
 Chemotherapy 86 2* -  
     .09 
ALL-BFM-95      
 SCT 36 4** -  
 Chemotherapy 57 5* 1***  
     .001 
*Deaths included- (both trials combined)- 4 from infection, 1 from cerebral hemorrhage, and 2 from 
thromboembolism 
**Deaths included- (occurred only after MUD/MMFD-SCT in ALL-BFM 95)- 2 from infection, 1 from infection 
plus graft failure, and 1 from veno-occlusive disease plus multiorgan failure 
***Other adverse events- 1 secondary malignancy 
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 The final study by Tallen et al., had a total of 525 participants that were further divided 
into three subgroups (A-early bone marrow (BM) relapses, B- late BM relapses, C- isolated 
extramedullary relapses, and PPG- poor prognosis group) based on their specific HR prognostic 
characteristics.
9
 Out of the 525, 323 patients received chemoradiotherapy alone and 117 received 
SCT (87 of the 117 were allogeneic SCT).  SCT significantly improved the probability of EFS 
(pEFS) in the HR patient group (groups A and PPG: n=84; pEFS= 33% +/- 5%; and HLA-
compatible allogeneic grafts only: n=53; pEFS= 40% +/- 7%) as compared to chemotherapy 
alone (n=76; pEFS= 20% +/- 5%; P <.005 or <.001, respectively).
9
  Tallen further analyzed the 
individual prognostic factors and in a multivariate Cox regression analysis SCT as a time-
dependent covariate (risk ratio for subsequent event after SCT v. chemotherapy alone, 1 v. 1.8, P 
<.001) proved to be an independent predictor of EFS.
9
  
 An analysis of adverse effects of the intervention (allogeneic SCT) was difficult in this 
study since post-remission therapy events were documented according to the subgroups (A, B, C, 
and PPG) and the patients who only received allogeneic SCT were not separated out of these 
groups. For purposes of this review, the post-remission therapy events for Groups A and PPG 
will be noted since they each had more patients receive SCT as compared to Groups B and C.
9
  A 
breakdown of such events are listed in Table 4.
9
 Overall, the NNH in this study was calculated 
to be 5 patients.   
Table 4- Adverse Events of Trial ALL-REZ BFM 90: Groups A and PPG 
 Group A Group PPG 
# of pts who received chemoradiotherapy 60 60 
# of pts who received SCT 45 39 
Induction Death 7 12 
Non-Response 14 41 
Treatment-related Death 13 9 
Subsequent Relapse 69 67 
Secondary Malignancy 2 1 
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DISCUSSION 
The three studies discussed in this selective EBM review all investigated the potential 
benefits of adding SCT to the treatment regimen of HR pediatric ALL patients; however, each 
had different variables that significantly affected their outcomes.  In Schrauder’s study, they 
compared the outcomes of HR-T-ALL patients who received allogeneic SCT with those of 
patients who received chemotherapy alone further analyzing the outcomes of SCT patients 
according to the type of donor finding that relapses only occurred after MSD-SCT and not the 
other subgroup; however, the low number of events did not allow for definite conclusions despite 
the statistically significant difference.  This study was the first to demonstrate that SCT in CR1 
had superior outcomes when compared to chemotherapy alone.
7 
Tallen et al. assessed the impact of SCT for experimental post-remission treatment in HR 
patients discovering that second CR rates and pEFS were significantly higher after allogeneic 
SCT than after chemoradiotherapy alone in HR, but not in intermediate-risk patients.  They also 
demonstrated that various prognostic factors (i.e. time point, site of relapse, ALL 
immunophenotype, and SCT time-dependent covariate) proved to all be independently 
associated with EFS in this trial and helped identify a stratification system that was used to 
determine the different subgroups that were analyzed in this study so that more specific treatment 
recommendations could be made.  This risk-based approach also helped them to determine that 
allogeneic SCT should be recommended as a treatment option for the PPG patient subgroup in 
ongoing trials.
9 
In contrast to the two previous studies mentioned above, the trial by Ribera et al. failed to 
prove that allogeneic SCT provides a better outcome than chemotherapy alone in children with 
VHR-ALL in first CR.  There were limitations in this trial such as the low frequency of VHR 
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patients, specifically those who have certain chromosomal translocations making it difficult to 
draw any definite conclusions in regards to the benefit of SCT in this population. Another 
limitation involved the time frame between achievement of CR and the beginning of the patient’s 
assigned therapy (i.e. SCT or chemotherapy alone). The patients assigned to SCT experienced a 
longer time frame than the patients who only received chemotherapy. There was also a lack of 
strict rules for the preparative regimen prior to SCT also making it difficult to draw definitive 
conclusions.  Despite the various concerns in this study, the overall outcomes achieved in this 
trial confirmed that the prognosis of VHR pediatric ALL patients remains poor even with the 
addition of SCT.
6 
CONCLUSION 
After reviewing the three articles discussed in this selective EBM review, the evidence is 
inconclusive and conflicting as to whether or not the addition of allogeneic SCT improves 
overall outcomes for HR pediatric ALL patients as compared to receiving chemotherapy alone.  
Each study in this review had very different and specific criteria that they used in determining 
patients HR, which influenced the results of the study making it difficult to identify definitive 
conclusions regarding the addition of SCT.  This area of research should definitely continue 
since some of the studies did show positive outcomes when SCT was added; however, these 
studies are limited in number.  There is also room for this specific area of research to be 
conducted more in the United States since the studies in this review were conducted in Europe.  
In summary, the prognosis of HR pediatric ALL patients has historically been poor, but the use 
of allogeneic SCT has proven some benefit despite its risks.  With this in mind, the need for 
ongoing research of this specific therapeutic intervention is absolutely imperative in an attempt 
to improve the overall survival of the HR pediatric ALL patient population.   
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